Join Growin Stock Community!

Virax biolabs group limitedVRAX.US Overview

US StockHealthcare
(No presentation for VRAX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VRAX AI Insights

VRAX Overall Performance

VRAX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VRAX Recent Performance

0.61%

Virax biolabs group limited

0.05%

Avg of Sector

-0.31%

S&P500

VRAX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VRAX Key Information

VRAX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VRAX Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Price of VRAX

VRAX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VRAX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
566.08
PB Ratio
0.31
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-8774.51%
Net Margin
-189001.71%
Revenue Growth (YoY)
-96.48%
Profit Growth (YoY)
-879.83%
3-Year Revenue Growth
-34.64%
3-Year Profit Growth
1097.17%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
566.08
PB Ratio
0.31
Price-to-FCF
-
Gross Margin
-8774.51%
Net Margin
-189001.71%
Revenue Growth (YoY)
-96.48%
Profit Growth (YoY)
-879.83%
3-Year Revenue Growth
-34.64%
3-Year Profit Growth
1097.17%

  • When is VRAX's latest earnings report released?

    The most recent financial report for Virax biolabs group limited (VRAX) covers the period of 2026Q2 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VRAX's short-term business performance and financial health. For the latest updates on VRAX's earnings releases, visit this page regularly.

  • What is the operating profit of VRAX?

    According to the latest financial report, Virax biolabs group limited (VRAX) reported an Operating Profit of -2.59M with an Operating Margin of -160,788.25% this period, representing a growth of 10.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is VRAX's revenue growth?

    In the latest financial report, Virax biolabs group limited (VRAX) announced revenue of 1.61K, with a Year-Over-Year growth rate of -67.53%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does VRAX have?

    As of the end of the reporting period, Virax biolabs group limited (VRAX) had total debt of 537.99K, with a debt ratio of 0.09. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VRAX have?

    At the end of the period, Virax biolabs group limited (VRAX) held Total Cash and Cash Equivalents of 3.35M, accounting for 0.59 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VRAX's EPS continuing to grow?

    According to the past four quarterly reports, Virax biolabs group limited (VRAX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.49. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VRAX?

    Virax biolabs group limited (VRAX)'s Free Cash Flow (FCF) for the period is -3.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 41.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.